<p>, /PRNewswire/ -- Tharimmune, Inc. (NASDAQ: THAR) 是首家利用 Canton Coin 支持 Canton Network 数字化传统金融市场的上市公司，今天宣布了一项 5500 万美元的注册发行定价。</p>
<p>Tharimmune, Inc. 通过积极参与 Canton Network，实施了一种差异化的数字资产财库策略，该网络是一个隐私保护、安全的区块链，链上托管着数万亿资产。</p>
<p>该发行预计将在 2026 年 1 月 21 日左右完成，具体取决于满足惯例的交割条件。交易包括以每股 2.92 美元的价格发行 1,800,000 股普通股，以及预先融资的认股权证，允许以每个预先融资认股权证 2.9199 美元的价格购买最多 17,000,000 股普通股。此次发行将为公司提供额外的增长资本，以继续扩展和发展其以 Canton 为中心的数字资产财库策略，并为一般企业用途提供营运资金。</p>
<p>Clear Street 担任此次发行的唯一账簿管理人。</p>
<p>上述证券由公司根据于 2026 年 1 月 9 日向证券交易委员会（SEC）提交的货架注册声明进行发行，该声明于 2026 年 1 月 16 日生效（文件编号 333-292648）。与此次发行相关的招股说明书补充及附带招股说明书于 2026 年 1 月 20 日提交给 SEC，并可通过联系 Clear Street，注意：承销部，150 Greenwich Street, 45th floor, New York, NY 10007，电子邮件地址为 ecm@clearstreet.io；或访问 SEC 网站 https://www.sec.gov/ 获取。</p>
<p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何法律禁止此类要约、邀请或销售的司法管辖区内进行这些证券的销售，除非在任何此类司法管辖区的证券法下进行注册或资格认证。</p>
<p><strong>关于 Tharimmune</strong></p>
<p>Tharimmune, Inc. (NASDAQ: THAR) 是首家利用 Canton Coin 并支持 Canton Network 以推动机构区块链采用和金融市场数字化的上市公司。除了通过在 Canton Network 上的活动创造价值外，Tharimmune 还进行临床阶段的生物技术研究与开发。有关更多信息，请访问 www.tharimmune.com。提及网站上包含的信息或可通过网站访问的信息并不构成对该信息的引用，您不应将此类信息视为本新闻稿的一部分。</p>
<p><strong>前瞻性声明</strong></p>
<p>本发布中所作的某些声明属于 1995 年美国私人证券诉讼改革法案的 “安全港” 条款下的 “前瞻性声明”，包括关于公司战略、计划、目标、举措和财务前景的声明。在本新闻稿中使用的 “估计”、“预测”、“期望”、“预期”、“预测”、“计划”、“意图”、“相信”、“寻求”、“可能”、“将”、“应该”、“未来”、“提议” 及这些词或类似表达的变体（或这些词或表达的否定版本）旨在识别前瞻性声明。这些前瞻性声明并不保证未来的表现、条件或结果，并涉及许多已知和未知的风险、不确定性、假设和其他重要因素，其中许多超出了公司的控制范围，可能导致实际结果或结果与前瞻性声明中讨论的内容有实质性差异。因此，读者应谨慎对待任何前瞻性声明。除法律要求外，公司不计划也不承担更新本声明中所作的任何前瞻性声明的义务。</p>
<p>投资者应仔细考虑上述因素，以及在公司截至 2024 年 12 月 31 日的年度报告 “第 1A 项：风险因素” 中描述的其他风险和不确定性，该报告于 2025 年 3 月 26 日向 SEC 提交，以及公司向 SEC 提交的其他文件，包括注册声明和公司提交的其他文件。这些文件识别并解决了可能导致实际事件和结果与前瞻性声明中包含的内容有实质性差异的其他重要风险和不确定性。</p>
<p><strong>联系方式</strong></p>
<p>媒体：</p>
<p>Gasthalter &amp; Co.</p>
<p>(212) 257-4170</p>
<p>canton@gasthalter.com</p>
<p>投资者：</p>
<p>ir@tharimmune.com</p>
<p><strong>X:</strong> @TharimmuneInc</p>
<p><strong>LinkedIn:</strong> https://www.linkedin.com/company/tharimmune-inc/</p>
<p><strong>网站：</strong> https://tharimmune.com/</p>
<p>来源 Tharimmune, Inc.</p>

<p>Tharimmune, Inc.（纳斯达克代码：THAR）宣布以 5500 万美元的承销注册发行定价，其中包括 180 万股普通股，价格为每股 2.92 美元，以及 1700 万股的预付认股权证，价格为每股 2.9199 美元。此次发行旨在为公司在 Canton Network 内的数字资产财务战略提供增长资本。该交易预计将在 2026 年 1 月 21 日左右完成，具体取决于常规条件。Clear Street 是此次发行的唯一账簿管理人</p>

<p>, /PRNewswire/ -- Tharimmune, Inc. (NASDAQ: THAR), the first publicly traded company to leverage Canton Coin to support the Canton Network's ability to digitize traditional financial markets, today announced the pricing of a $55 million registered offering.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Tharimmune, Inc. (NASDAQ: THAR) 是首家利用 Canton Coin 支持 Canton Network 数字化传统金融市场的上市公司，今天宣布了一项 5500 万美元的注册发行定价。</p>
</div><p>Tharimmune, Inc. operates a differentiated digital asset treasury strategy by actively participating in the Canton Network – a privacy-enabled, secure blockchain hosting trillions in assets on chain.</p>
<div class="lb-trans"><p>Tharimmune, Inc. 通过积极参与 Canton Network，实施了一种差异化的数字资产财库策略，该网络是一个隐私保护、安全的区块链，链上托管着数万亿资产。</p>
</div><p>The offering is expected to close on or about January 21, 2026, subject to the satisfaction of customary closing conditions. The transaction includes the issuance of 1,800,000 shares of its common stock at a price of $2.92 per share and pre-funded warrants to purchase up to 17,000,000 shares of common stock at a price of $2.9199 per pre-funded warrant. The offering will provide the Company with additional growth capital for the continued expansion and development of its Canton-centric digital asset treasury strategy, as well as with working capital for general corporate purposes.</p>
<div class="lb-trans"><p>该发行预计将在 2026 年 1 月 21 日左右完成，具体取决于满足惯例的交割条件。交易包括以每股 2.92 美元的价格发行 1,800,000 股普通股，以及预先融资的认股权证，允许以每个预先融资认股权证 2.9199 美元的价格购买最多 17,000,000 股普通股。此次发行将为公司提供额外的增长资本，以继续扩展和发展其以 Canton 为中心的数字资产财库策略，并为一般企业用途提供营运资金。</p>
</div><p>Clear Street is acting as sole bookrunner for the offering.</p>
<div class="lb-trans"><p>Clear Street 担任此次发行的唯一账簿管理人。</p>
</div><p>The securities described above are being offered by the Company pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (SEC) on January 9, 2026 and became effective on January 16, 2026 (File No. 333-292648). A prospectus supplement and accompanying prospectus relating to and describing the terms of the offering were filed with the SEC on January 20, 2026 and may be obtained by contacting Clear Street, Attn: Syndicate Department, 150 Greenwich Street, 45th floor, New York, NY 10007, by email at ecm@clearstreet.io; or by accessing the SEC's website at https://www.sec.gov/.</p>
<div class="lb-trans"><p>上述证券由公司根据于 2026 年 1 月 9 日向证券交易委员会（SEC）提交的货架注册声明进行发行，该声明于 2026 年 1 月 16 日生效（文件编号 333-292648）。与此次发行相关的招股说明书补充及附带招股说明书于 2026 年 1 月 20 日提交给 SEC，并可通过联系 Clear Street，注意：承销部，150 Greenwich Street, 45th floor, New York, NY 10007，电子邮件地址为 ecm@clearstreet.io；或访问 SEC 网站 https://www.sec.gov/ 获取。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售这些证券的要约或购买这些证券的要约邀请，也不应在任何法律禁止此类要约、邀请或销售的司法管辖区内进行这些证券的销售，除非在任何此类司法管辖区的证券法下进行注册或资格认证。</p>
</div><p><strong>About Tharimmune</strong></p>
<div class="lb-trans"><p><strong>关于 Tharimmune</strong></p>
</div><p>Tharimmune, Inc. (NASDAQ: THAR) is the first publicly traded company to leverage Canton Coin and support the Canton Network to advance institutional blockchain adoption and the digitization of financial markets. In addition to driving value through activities on the Canton Network, Tharimmune also operates clinical-stage biotech research and development. For more information, visit www.tharimmune.com. References to information included on, or accessible through, websites do not constitute incorporation by reference of the information contained at or available through such websites, and you should not consider such information to be part of this press release.</p>
<div class="lb-trans"><p>Tharimmune, Inc. (NASDAQ: THAR) 是首家利用 Canton Coin 并支持 Canton Network 以推动机构区块链采用和金融市场数字化的上市公司。除了通过在 Canton Network 上的活动创造价值外，Tharimmune 还进行临床阶段的生物技术研究与开发。有关更多信息，请访问 www.tharimmune.com。提及网站上包含的信息或可通过网站访问的信息并不构成对该信息的引用，您不应将此类信息视为本新闻稿的一部分。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Certain statements made in this release are &#34;forward looking statements&#34; within the meaning of the &#34;safe harbor&#34; provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company's strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words &#34;estimates,&#34; &#34;projected,&#34; &#34;expects,&#34; &#34;anticipates,&#34; &#34;forecasts,&#34; &#34;plans,&#34; &#34;intends,&#34; &#34;believes,&#34; &#34;seeks,&#34; &#34;may,&#34; &#34;will,&#34; &#34;should,&#34; &#34;future,&#34; &#34;propose&#34; and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.</p>
<div class="lb-trans"><p>本发布中所作的某些声明属于 1995 年美国私人证券诉讼改革法案的 “安全港” 条款下的 “前瞻性声明”，包括关于公司战略、计划、目标、举措和财务前景的声明。在本新闻稿中使用的 “估计”、“预测”、“期望”、“预期”、“预测”、“计划”、“意图”、“相信”、“寻求”、“可能”、“将”、“应该”、“未来”、“提议” 及这些词或类似表达的变体（或这些词或表达的否定版本）旨在识别前瞻性声明。这些前瞻性声明并不保证未来的表现、条件或结果，并涉及许多已知和未知的风险、不确定性、假设和其他重要因素，其中许多超出了公司的控制范围，可能导致实际结果或结果与前瞻性声明中讨论的内容有实质性差异。因此，读者应谨慎对待任何前瞻性声明。除法律要求外，公司不计划也不承担更新本声明中所作的任何前瞻性声明的义务。</p>
</div><p>Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the &#34;Item 1A. Risk Factors&#34; in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 26, 2025 and the Company's filings with the SEC, including the registration statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.</p>
<div class="lb-trans"><p>投资者应仔细考虑上述因素，以及在公司截至 2024 年 12 月 31 日的年度报告 “第 1A 项：风险因素” 中描述的其他风险和不确定性，该报告于 2025 年 3 月 26 日向 SEC 提交，以及公司向 SEC 提交的其他文件，包括注册声明和公司提交的其他文件。这些文件识别并解决了可能导致实际事件和结果与前瞻性声明中包含的内容有实质性差异的其他重要风险和不确定性。</p>
</div><p><strong>Contacts</strong></p>
<div class="lb-trans"><p><strong>联系方式</strong></p>
</div><p>Media:</p>
<div class="lb-trans"><p>媒体：</p>
</div><p>Gasthalter &amp; Co.</p>
<div class="lb-trans"><p>Gasthalter &amp; Co.</p>
</div><p>(212) 257-4170</p>
<div class="lb-trans"><p>(212) 257-4170</p>
</div><p>canton@gasthalter.com</p>
<div class="lb-trans"><p>canton@gasthalter.com</p>
</div><p>Investors:</p>
<div class="lb-trans"><p>投资者：</p>
</div><p>ir@tharimmune.com</p>
<div class="lb-trans"><p>ir@tharimmune.com</p>
</div><p><strong>X:</strong> @TharimmuneInc</p>
<div class="lb-trans"><p><strong>X:</strong> @TharimmuneInc</p>
</div><p><strong>LinkedIn:</strong> https://www.linkedin.com/company/tharimmune-inc/</p>
<div class="lb-trans"><p><strong>LinkedIn:</strong> https://www.linkedin.com/company/tharimmune-inc/</p>
</div><p><strong>Website:</strong> https://tharimmune.com/</p>
<div class="lb-trans"><p><strong>网站：</strong> https://tharimmune.com/</p>
</div><p>SOURCE Tharimmune, Inc.</p>
<div class="lb-trans"><p>来源 Tharimmune, Inc.</p>
</div>

Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering | THAR Stock News

StockTitan

2 倍做多纳斯达克生物技术 ETF - ProShares

Tharimmune

Invesco Nasdaq Biotechnology ETF

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

医疗业 ETF - Vanguard

动态生物技术与基因组 ETF - Invesco

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

医疗业 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

Tharimmune, Inc. 宣布其 5500 万美元的包销注册发行定价 | THAR 股票新闻